The 27 most recent market catalysts affecting $CI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bearish
Impact 55
Radiotherapy Access Alliance Files Lawsuit Challenging EviCore Guideline Changes
The Radiotherapy Access Alliance has sued EviCore, a Cigna subsidiary, over its decision to no longer cover low-dose radiation therapy (LDRT) for conditions like arthritis and plan…
Nov 14, 2026
Corporate Catalyst
Neutral
Impact 65
U.S. Senators Launch Inquiry into Health Insurers' Prior Authorization Practices
U.S. Senators Jon Ossoff, Sheldon Whitehouse, and Ron Wyden have initiated formal inquiries with six major health insurance companies, including The Cigna Group, regarding their Ju…
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Adjusts Price Target on Cigna to $360 From $370
Piper Sandler, a prominent investment bank, has revised its price target for Cigna (CI) from $370 to $360. This downward adjustment signals a slightly reduced expectation for the c…
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 65
Piper Sandler Downgrades Cigna to Neutral
Piper Sandler downgraded The Cigna Group's stock to Neutral, signaling a less optimistic outlook on the company's future performance. This action typically leads to a negative shor…
Nov 12, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Adjusts Price Target on Cigna to $360 From $370
Piper Sandler, a prominent investment bank, has adjusted its price target for Cigna Group, lowering it from $370 to $360. This change reflects a revised valuation outlook by the an…
Nov 11, 2026
Corporate Catalyst
Bearish
Impact 65
Bernstein Downgrades Cigna Group Rating to Sell
On November 11, 2026, Bernstein downgraded The Cigna Group's stock from Neutral to Sell. This analyst action signals a more bearish sentiment from a prominent financial institution…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 85
The Cigna Group Reports Third Quarter 2026 Results and Raises 2026 Outlook
Cigna reported third-quarter 2026 total revenues of $73.7 billion, a 6% increase, and adjusted income from operations of $7.98 per share. This strong performance led the company to…
Nov 3, 2026
Corporate Catalyst
Bearish
Impact 55
The Cigna Group Objects to Tokenized Share Listing
The Cigna Group has exercised its right to object to the listing of tokenized shares on the OKX-ICE TSV platform, a move that successfully blocks the creation and trading of these …
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 65
Cigna and Other Insurers Scrutinized Over Mental Health Crisis Care Payments in California
Cigna, Anthem Blue Cross, and UnitedHealthcare are facing significant scrutiny for rejecting approximately $4.1 million in mental health crisis claims in California since 2024. Thi…
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 65
Mark Cuban Alleges Major Insurers Overcharge Employers on Health Plans
Billionaire investor Mark Cuban reported that several public companies, using AI, found they were significantly overcharged by major insurers Cigna, UnitedHealth Group, and CVS Hea…
Oct 31, 2026
Corporate Catalyst
Neutral
Impact 75
Department of Labor Finalizes PBM Transparency Rule
The U.S. Department of Labor finalized a new rule mandating that Pharmacy Benefit Managers (PBMs) disclose detailed financial information, including spread pricing and rebates, to …
Oct 27, 2026
Corporate Catalyst
Bearish
Impact 75
US Senators Investigate Cigna and Other Insurers Over ACA Enrollee Removals
US Senator Bernie Sanders and other Democratic lawmakers have launched an investigation into Cigna and nine other major private insurance companies regarding the termination of ACA…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 65
Robert Kennedy Jr. Pushes New Healthcare Pricing Rules as HHS Says Patients Deserve Clearer Costs: ‘Americans Should Know…’
The U.S. Department of Health and Human Services (HHS) has finalized new regulations to improve healthcare pricing transparency, requiring group health plans and insurers to provid…
Oct 2, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on Cigna Group, Raises Price Target to $370
This filing discloses that Piper Sandler has maintained its 'Overweight' rating on Cigna Group (CI) and raised its price target from $346 to $370. This analyst action is a positive…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 75
CI stock has given up its prior loss. Cigna Group shares were trading lower after the company affirmed its FY26 sales guidance below estimates.
The primary impact here is on Cigna Group (CI) due to its affirmed FY26 sales guidance falling short of analyst expectations. This initially caused a negative reaction, but the sub…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 75
Cigna Group shares are trading lower after the company affirmed its FY26 sales guidance below estimates.
The primary impact is negative for Cigna (CI) as the market reacts to the lower-than-expected sales guidance for FY26. While the company affirmed its long-term outlook, the immedia…
Sep 30, 2026
Corporate Catalyst
Neutral
Impact 75
Cigna Group Affirms FY2026 Adj EPS Of At Least $30.45 Vs $30.41 Est; Affirms FY2026 Revenue Of ~$280.000B Vs $285.608B Est
This headline presents a mixed but generally positive outlook for Cigna. The affirmation of FY2026 adjusted EPS above estimates indicates strong underlying profitability and potent…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 55
Cigna Healthcare Expands AI-Enabled Personalized Support To Help More Customers Access Care Earlier, Improve Affordability
Cigna Healthcare announced the expansion of its AI-enabled personalized support, aiming to improve customer access to care and affordability. This move signifies a strategic invest…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 65
Jefferies Downgrades Cigna Group to Hold, Lowers Price Target to $307
Jefferies analyst David Windley downgraded Cigna Group (CI) from a 'Buy' to a 'Hold' rating and lowered the price target from $336 to $307. This move signals a less optimistic outl…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
Raymond James Downgrades Cigna Group to Outperform, Lowers Price Target to $320
Raymond James analyst John Ransom downgraded Cigna Group (CI) from 'Strong Buy' to 'Outperform' and lowered the price target from $350 to $320. This action signals a reduced level …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Cigna Group, Raises Price Target to $361
Guggenheim analyst Jason Cassorla has maintained a 'Buy' rating on Cigna Group (CI) and raised the price target from $338 to $361. This action signals a strong vote of confidence f…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Cigna Group, Raises Price Target to $310
Barclays analyst Andrew Mok maintained an 'Equal-Weight' rating on Cigna Group (CI) but raised the price target from $304 to $310. This indicates a slightly improved valuation pers…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions
Cigna's Q2 2026 results showed an earnings and revenue beat, leading to an upward revision of its full-year adjusted EPS guidance. This would typically be a positive catalyst. Howe…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Cigna Group shares are trading lower. The company reported Q2 financial results.
The headline indicates a direct corporate catalyst for Cigna (CI), with its Q2 results driving immediate share price depreciation. This event is significant because Cigna is a majo…
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 75
Cigna Group FY2026 Adj EPS expected to be more than $30.45 vs $30.41 Est
Cigna Group (CI) filed an 8-K disclosing that its fiscal year 2026 adjusted EPS is projected to be more than $30.45, exceeding the current analyst estimate of $30.41. This is a pos…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Cigna Group Q2 Adj. EPS $7.78 Beats $7.60 Estimate, Sales $71.558B Beat $70.339B Estimate
Cigna Group's Q2 earnings and sales significantly surpassed analyst estimates, demonstrating strong financial performance. The adjusted EPS of $7.78 beat the $7.60 estimate by 2.37…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.